Thus, targeting m6A-E7 mRNA-IGF2BP1 condensates could be a promising therapeutic strategy for HPV-associated cancers, highlighting the clinical potential of anti-tumor therapy by focusing on m6A-associated MLOs. This evidence concerns the gene IGF2BP1 and cancer.